Next Article in Journal
NEDD9 Inhibition by miR-25-5p Activation Is Critically Involved in Co-Treatment of Melatonin- and Pterostilbene-Induced Apoptosis in Colorectal Cancer Cells
Previous Article in Journal
The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells
Article

Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients

1
Institute for Pharmacology and Clinical Pharmacology, University Hospital of the Heinrich-Heine-University, 40225 Düsseldorf, Germany
2
Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany
3
Agena Bioscience GmbH, 22761 Hamburg, Germany
4
Department of Dermatology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany
5
Department of Dermatology, Elbe Kliniken, 21614 Buxtehude, Germany
6
Institute of Transfusion Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
7
DermatoMed, 22303 Hamburg, Germany
*
Author to whom correspondence should be addressed.
Joint authorship.
Cancers 2019, 11(11), 1685; https://doi.org/10.3390/cancers11111685
Received: 21 September 2019 / Revised: 20 October 2019 / Accepted: 25 October 2019 / Published: 29 October 2019
Despite remarkable progress in melanoma therapy, the exceptional heterogeneity of the disease has prevented the development of reliable companion biomarkers for the prediction or monitoring of therapy responses. Here, we show that difficulties in detecting blood-based markers, like circulating tumor cells (CTC), might arise from the translation of the mutational heterogeneity of melanoma cells towards their surface marker expression. We provide a unique method, which enables the molecular characterization of clinically relevant CTC subsets, as well as circulating tumor DNA (ctDNA), from a single blood sample. The study demonstrates the benefit of a combined analysis of ctDNA and CTC counts in melanoma patients, revealing that CTC subsets and ctDNA provide synergistic real-time information on the mutational status, RNA and protein expression of melanoma cells in individual patients, in relation to clinical outcome. View Full-Text
Keywords: melanoma; ctDNA; CTC; liquid biopsy melanoma; ctDNA; CTC; liquid biopsy
Show Figures

Figure 1

MDPI and ACS Style

Gorges, K.; Wiltfang, L.; Gorges, T.M.; Sartori, A.; Hildebrandt, L.; Keller, L.; Volkmer, B.; Peine, S.; Babayan, A.; Moll, I.; Schneider, S.W.; Twarock, S.; Mohr, P.; Fischer, J.W.; Pantel, K. Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients. Cancers 2019, 11, 1685. https://doi.org/10.3390/cancers11111685

AMA Style

Gorges K, Wiltfang L, Gorges TM, Sartori A, Hildebrandt L, Keller L, Volkmer B, Peine S, Babayan A, Moll I, Schneider SW, Twarock S, Mohr P, Fischer JW, Pantel K. Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients. Cancers. 2019; 11(11):1685. https://doi.org/10.3390/cancers11111685

Chicago/Turabian Style

Gorges, Katharina, Lisa Wiltfang, Tobias M. Gorges, Alexander Sartori, Lina Hildebrandt, Laura Keller, Beate Volkmer, Sven Peine, Anna Babayan, Ingrid Moll, Stefan W. Schneider, Sören Twarock, Peter Mohr, Jens W. Fischer, and Klaus Pantel. 2019. "Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients" Cancers 11, no. 11: 1685. https://doi.org/10.3390/cancers11111685

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop